Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost versions of drugs on standard formularies.
Source: BioPharma Dive
You may also like
EC approves Erbitux combination for first‑line...
FDA approves Leqembi Iqlik subcutaneous initiation...
AstraZeneca agrees on $1.5bn deal with Dizal...
Cherry appoints Peter Henshaw as new Managing Director
Novel Epigenetic Therapy Targets Treatment-Resistant...
FDA Issues Proposal to Streamline Registration for...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.